Xylego
A low-burden treatment that
can be used in combination with
conventional therapy
What
is
IBD
Patients with ulcerative gastrocoliitis who were unable to maintain remission rate
33%
2017
IBD Patients
7,000,000
people
worldwide
Why is IBD difficult to treat?
01
Low
remission
rate
02
vicious
cycle of
inflammation
03
Medication
non
adherence
Our Solution
Low-cost treatments that can be used in conjunction with existing medications
Phase #1
colonization support
Uses xylitol, which other intestinal bacteria cannot use, as a carbon source to promote colonization, thereby reducing the required administration frequency.
Phase #2
EGF production
After colonization in the gut, the strain produces EGF. Epidermal Growth Factor (EGF) acts on damaged epithelial cells, exerting a mucosal healing effect throughout the intestinal tract.
Phase #3
kill switch
Commits suicide after treatment is completed to minimize side effects.It can prevent side effects from EGF and the spread of genetically modified microorganisms.Furthermore, by cleaving antibiotic resistance genes, their spread can be prevented.
Over
view of
Design
text text text text text text text text text text text text
Xylitol
assimilation
EGF
Production
Kill
Switch
Design
Description
Model
Integrated Human Practice
Member
Design
Our innovative design approach focuses on engineering E. coli Nissle 1917 to produce therapeutic compounds. The design integrates three key components: xylitol utilization for selective growth, EGF production for tissue healing, and a kill switch for safety.
Learn more about DesignDescription
Our project aims to develop a novel therapeutic approach for Inflammatory Bowel Disease (IBD) using engineered probiotics. By modifying E. coli Nissle 1917, we create a targeted delivery system for growth factors that can help heal damaged intestinal tissue.
Learn more about DescriptionModel
We developed comprehensive mathematical models to predict the behavior of our engineered system. These models help us understand the kinetics of xylitol metabolism, EGF production rates, and the effectiveness of our kill switch mechanism.
Learn more about ModelIntegrated Human Practice
Our human practices work involved extensive engagement with patients, healthcare professionals, and regulatory experts. We conducted interviews and surveys to understand the real-world needs and concerns regarding IBD treatment.
Learn more about Integrated Human PracticeMember
Our diverse team consists of undergraduate students from various disciplines including biotechnology, bioengineering, and life sciences. Each member brings unique expertise and perspective to our collaborative research effort.
Learn more about Member